Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever

The Journal of International Medical Research
Ying LuanZhongying Bao

Abstract

To study the pathogenic bacterial profile and drug resistance in older patients with community-acquired pneumonia (CAP) in outpatients with fever, and provide evidence to diagnose and treat CAP timely and accurately. We studied older (>60 years) patients with CAP in Beijing Shijitan Hospital from 2016 to 2017. Pathogenic bacteria from sputum of patients were isolated and identified and their resistance to antibiotics was tested. Risk factors for multidrug-resistant CAP (MDR-CAP) and clinical outcomes were analyzed. A total of 5563 outpatients with fever were recruited and 391 had CAP. A total of 117 isolates of pathogenic bacteria were obtained from 176 CAP cases. The main pathogenic bacteria were Klebsiella pneumoniae (27.4%), Escherichia coli (17.9%), Staphylococcus aureus (12.0%), Pseudomonas aeruginosa (10.3%), and Streptococcus pneumoniae (9.4%). A drug sensitivity test (DST) showed that K. pneumoniae, E. coli, and P. aeruginosa had good sensitivity to imipenem, cefoperazone/sulbactam, piperacillin/tazobactam, and amikacin. Staphylococcus aureus and Streptococcus pneumoniae had strong sensitivity to vancomycin, linezolid, and levofloxacin. Previous multiple antibiotic treatment was an independent risk factor for MDR-CAP. G...Continue Reading

References

May 1, 1993·American Journal of Epidemiology·C JokinenS Soimakallio
Aug 26, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F BaqueroJ Blázquez
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·M S NiedermanUNKNOWN American Thoracic Society
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Dec 29, 2007·International Journal of Antimicrobial Agents·Jae-Hoon SongUNKNOWN Asian Network for Surveillance of Resistant Pathogens Study Group
Oct 14, 2009·Thorax·W S LimUNKNOWN Pneumonia Guidelines Committee of the BTS Standards of Care Committee
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James D ChalmersAdam T Hill
May 2, 2014·Transactions of the Royal Society of Tropical Medicine and Hygiene·Leon PetoHeiman F L Wertheim
Jul 15, 2015·The New England Journal of Medicine·Seema JainUNKNOWN CDC EPIC Study Team
Jan 10, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Naomi J GadsbyKate E Templeton

❮ Previous
Next ❯

Citations

Jul 17, 2020·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Gang ChenBangjiang Fang
Sep 3, 2021·Lung India : Official Organ of Indian Chest Society·Deepjyoti KalitaSangeeta Deka

❮ Previous
Next ❯

Methods Mentioned

BETA
light microscopy

Software Mentioned

SPSS

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.